



Published in final edited form as:

Anal Chem. 2011 September 15; 83(18): 7123–7128. doi:10.1021/ac2014756.

Label-acquired magnetorotation as a signal transduction method for protein detection: aptamer-based detection of thrombin

Ariel Hecht, Anand Akshay Kumar, and Raoul Kopelman*

University of Michigan, Ann Arbor, Michigan 48109, United States

Abstract

This paper presents a new signal transduction method, called Label-Acquired Magnetorotation (LAM), for the measurement of proteins in solution. We demonstrate the use of LAM to detect the protein thrombin using aptamers, with an LOD (limit of detection) of 300 pM. LAM is modeled after a sandwich assay, with a 10 μm nonmagnetic “mother” sphere as the capture component, and with 1 μm magnetic “daughter” beads as the labels. The protein-mediated attachment of daughter beads to the mother sphere forms a rotating sandwich complex. In a rotating magnetic field, the rotational frequency of a sandwich complex scales with the number of attached magnetic beads, which scales with the concentration of the protein present in solution. This paper represents the first instance of the detection of a protein using LAM.

Introduction

One of the primary goals in a point-of-care diagnostic system is measuring the concentration of a protein in order to assess the overall health of a patient. Effective screening methods have been shown to improve patient health, such as a recent large study, on a population at high risk for lung cancer, that found a 20% decrease in mortality due to better early screening^{1–2}. There are three primary components in a protein measurement system: the target biomarker to be measured, the affinity molecules used to capture the target, and the method of transducing a successful binding event into a quantifiable signal. There are several popular signal transduction methods, including optical, electrochemical and magnetic schemes. This paper presents the development of a new, optomagnetic signal transduction method, called label-acquired magnetorotation (LAM), which has the potential for eventual incorporation into a point-of-care diagnostic system. Previously, we published proof-of-principle work demonstrating the concept of LAM using a biotin and streptavidin system as protein and aptamer mimics.³ Here, we demonstrate the next step by showing LAM used to detect proteins in solution using aptamers.

The most common set-up for measuring the concentration of a protein in solution is the sandwich assay, where the target is first captured by an affinity molecule bound to a surface, and is then sandwiched by a signal transducer attached to another affinity molecule.⁴ Optical methods include sandwich-based ELISA,^{5–7} fluorescence signaling^{8–10} or quantum dots,^{11–12} and the non-sandwich based surface plasmon resonance methods.^{13–15} The electrochemical methods include sandwich-based amperometric enzymatic methods^{16–17} and non-sandwich-based impedimetric sensing.^{18–19}

Magnetic beads are advantageous for use as signal transducers because they are biologically inert, are physically stable under most biological environments, and biological materials have no native magnetism that could interfere with a signal from the beads.^{20–21} Due to these advantages, magnetic beads have been used as signal transducers in a variety of applications, including giant magnetoresistance (GMR),^{22–24} Hall probes,^{25–26} and magnetic relaxation.^{27–28} Additionally, magnetic beads have been used as carriers for magnetophoresis and to facilitate detection by other signal transduction methods.^{29–31} In contrast, the method described here uses optical detection of the magnetic behavior.

The beads used in this study are 1 μm commercial beads that exhibit superparamagnetic behavior (DynaBeads®). These beads are composed of maghemite ($\gamma\text{-Fe}_2\text{O}_3$) nanoparticles, with a mean diameter of 8 nm dispersed within a polymer bead. The beads are 25.5% Fe by mass.³² In the absence of a magnetic field, these beads have no net magnetization, but within a magnetic field, the magnetic moments of the beads align with the field and they become strongly magnetic.³²

The work presented here uses these beads in a rotating magnetic field. Previous studies have examined and characterized the behavior of these beads in alternating magnetic fields. It was first shown that in a one-dimensional alternating magnetic field, the dominant relaxation mechanism of such superparamagnetic beads is the Neel relaxation of the nanoparticles embedded within the bead.³³ It was later shown that in a two-dimensional rotating magnetic field, at high driving frequencies, the dominant mechanism driving the rotation of these same beads is also related to Neel relaxation.³⁴ Brownian rotational effects are not significant for these beads because the time constant for the Brownian relaxation of a sphere with diameter on the order of a micron is on the order of seconds, while the time constant for the Neel relaxation of the inner magnetic nanoparticles is on the order of nanoseconds.

In a two-dimensional rotating magnetic field, at low driving frequencies, magnetic beads are able to rotate synchronously with the field. At higher driving frequencies (above the critical frequency³⁵) these beads are not able to stay in phase with the field, and rotate asynchronously. In the asynchronous regime, the rotational frequency of the bead depends on a number of factors, including the magnetic moment of the bead, the amplitude and frequency of the driving field, the hydrodynamic volume of the bead, and the viscosity of the solution. This asynchronous rotation has already been demonstrated to be a useful tool for making biological measurements, specifically for monitoring the growth and antibiotic susceptibility of bacteria.^{36–39}

Thrombin is a coagulation factor that is the first step in the coagulation cascade that leads to the formation of a blood clot, so as to stem blood loss. Aptamers are single- or double-stranded nucleic acid sequences that bind to proteins through favorable electrostatic interactions, with an affinity similar to that of an antibody.^{40–41} One of the earliest aptamers to be identified binds to the fibrin exosite on thrombin, and has the following 15-base pair sequence: 5'-GGTTGGTGTGGTTGG-3'.⁴² Later, a second, 29-base pair sequence against thrombin was identified, which binds to the heparin exosite: 5'-GTCCGTGGTAGGGCAGGTTGGGGTGAC-3'.⁴³ Since these aptamers bind to opposite sides of the thrombin molecule, they represent an ideal system for the development of an aptamer-based sandwich assay, and have been used in the development of many such assays.^{44–46}

Experimental

A schematic of LAM is shown in Figure 1. The mother spheres used were 10 μm nonmagnetic streptavidin-coated ProActive microspheres (Bangs Labs, Fishers, IN). The daughter beads used were Dynal MyOne 1 μm streptavidin-coated DynaBeads that exhibit

superparamagnetic behavior (Invitrogen, Carlsbad, CA). Human α -thrombin was purchased from Haematologic Technologies (Essex Junction, VT). Biotinylated aptamers (with a 5' polyT₂₀ tail for improved binding)⁴⁷ were purchased from Integrated DNA Technologies (Coralville, IA). Salts (NaCl, KCl, MgCl₂, EDTA and Tris-HCl) and Tween-20 were purchased from Sigma Aldrich (St. Louis, MO). Bovine serum albumin (BSA) Blocker solution was purchased from Thermo Scientific (Waltham, MA). Zero-thickness glass coverslips were obtained from Electron Microscopy Sciences (Hatfield, PA). OPI Top Coat clear nail protector was purchased from OPI Products Inc. (North Hollywood, CA). Formulations for wash buffer, aptamer binding buffer, and thrombin binding buffer (containing 0.1% BSA, and with the addition of 10 mM KCl⁴⁸) were based on previously published work.⁴⁷

An aliquot of 50 μ L of the magnetic beads was washed three times by magnetic separation in 200 μ L of wash buffer, then resuspended in 500 μ L of aptamer binding buffer, at a concentration of 1 mg/mL beads in a microcentrifuge tube. An aliquot of 50 μ L of the mother spheres was washed three times by centrifugation in 200 μ L of wash buffer, then resuspended in 1 mL of aptamer binding buffer, at a concentration of 0.5 mg/mL spheres. A 10 μ L aliquot of biotinylated-15-mer thrombin binding aptamer was added to the superparamagnetic beads, and a 10 μ L aliquot of biotinylated-29-mer thrombin binding aptamer was added to the mother spheres. The two solutions were briefly vortexed then incubated on an end-over-end rotator for 1 hour. They were then washed (by magnetic separation and centrifugation, respectively) three times and resuspended in thrombin binding buffer. An aliquot of human α -thrombin was serially diluted over a concentration range of 50 nM to 100 pM in thrombin binding buffer. In a separate tube, 100 μ L of thrombin solution were mixed with 40 μ L of mother sphere solution, and then incubated on an end-over-end rotator for 90 minutes. Finally, 10 μ L of magnetic bead solution were added to the mother spheres and thrombin and incubated on an end-over-end rotator for 90 minutes.

Microfluidic flow cells were prepared from two zero-thickness glass coverslips (the bottom coverslip was coated with a thin layer of clear nail protector, to reduce particle sticking) separated by a single piece of double-sided Scotch tape (3M, St. Paul, MN). The solution containing the mother spheres and the magnetic beads was diluted with 140 μ L of 0.2% Tween-20, and 20 μ L of this solution were pipetted into the coverslip flow cell. The coverslip flow cell was then placed in a rotating magnetic field (amplitude 1.25 mT, frequency 200 Hz) built from two pairs of orthogonally-oriented Helmholtz coils driven by a pair of sinusoidal waves 90 degrees out of phase with each other. The magnetic field was located on top of an IX71 inverted microscope (Olympus, Melville, NY). The rotation of the sandwich complexes was observed through a 100 \times oil-immersion objective, imaged through a Basler piA640-210gm camera (Basler, Highland, IL) and recorded by an in-house program written in LabVIEW (National Instruments, Austin, TX). Videos were analyzed using the St. Andrews particle tracker⁴⁹ and an in-house program written in MATLAB.

Theory

The theory governing the behavior of superparamagnetic particles and beads in rotating magnetic fields has been discussed in detail elsewhere.^{3, 33–34, 50} Briefly, starting from the equation for the magnetic torque, $\boldsymbol{\tau} = \mathbf{m} \times \mathbf{B}$, where \mathbf{m} is the magnetic moment of the bead and \mathbf{B} is the external magnetic field, assuming steady-state rotation (allowing for the

equating of rotational driving forces with drag forces, $\tau = \kappa \eta V_H \frac{d\theta}{dt}$, where κ is the shape factor (equal to 6 for a sphere), η is the viscosity of the surrounding fluid, and V_H is the hydrodynamic volume), and making some simple substitutions, $\mathbf{B} = \mu_0 \mathbf{H}$, $\mathbf{m} = M V_m$, $\mathbf{M} = \chi \mathbf{H}$ and $\chi = \chi' - i\chi''$ (where \mathbf{H} is the magnetizing field, μ_0 is the permeability of free space, \mathbf{M} is

the volume magnetization, V_m is the volume of the bead's magnetic material, χ is the bead susceptibility, χ' is the real component of the bead susceptibility and χ'' is the imaginary component of the bead susceptibility) we can get an expression for the rotational frequency $d\theta/dt$:

$$\frac{d\theta}{dt} = \frac{1}{k\eta V_H} \mu_0 V_m \chi'' H^2 \quad (1)$$

The definition of imaginary susceptibility, χ'' , is $\chi'' = \chi_0 \frac{\Omega \tau_N}{1 + \Omega^2 \tau_N^2}$, where χ_0 is the DC susceptibility, Ω is the frequency of the driving field. The definition of Neel relaxation time,

τ_N , is $\tau_N = \tau_0 \exp\left(\frac{KV_p}{k_B T}\right)$, where τ_0 is the attempt frequency, K is the anisotropy constant (equal to $5 \times 10^4 \text{ J/m}^3$ for maghemite nanoparticles⁵¹), V_p is the volume of the maghemite nanoparticles, k_B is Boltzmann's constant, and T is the ambient temperature. The magnetic nanoparticles are not perfectly uniform; for a size distribution with n intervals, with average nanoparticle volume V_p , the total volume of nanoparticles in the distribution is V_n . The expression for Neel relaxation time, τ_N , can be substituted into the expression for imaginary susceptibility, χ'' , which, along with considering the effects of the nanoparticle size distribution, can then be substituted into equation (1) to create a single expression describing the rotation of a superparamagnetic object in a magnetic field:³⁴

$$\frac{d\theta}{dt} = \frac{1}{k\eta V_H} \mu_0 V_m H^2 \chi_0 \frac{1}{\sum_n V_n^2} \sum_n \frac{\Omega \tau_0 \exp\left(\frac{KV_p}{k_B T}\right)}{1 + \Omega^2 \exp\left(\frac{2KV_p}{k_B T}\right)} V_n^2 \quad (2)$$

In the low driving frequency ($\Omega \ll 1 \text{ kHz}$) regime used in this paper, $\Omega^2 \exp\left(\frac{2KV_p}{k_B T}\right) \ll 1$, so equation (2) can be simplified:

$$\frac{d\theta}{dt} = \frac{1}{k\eta V_H} \mu_0 V_m H^2 \chi_0 \frac{1}{\sum_n V_n^2} \sum_n \Omega \tau_0 \exp\left(\frac{KV_p}{k_B T}\right) V_n^2 \quad (3)$$

Results and Discussion

To test whether the sandwich complexes follow the model of equation (3), we observed the response of the sandwich complexes to changes in amplitude and frequency. Holding all

variables except for field amplitude constant, equation (3) reduces to $\frac{d\theta}{dt} \propto H^2$. Figure 2a shows indeed that the rotational frequency of a sandwich complex is directly proportional to the square of the amplitude of the driving field. Holding all variables constant except for

field driving frequency, equation (3) reduces to $\frac{d\theta}{dt} \propto \Omega$. Figure 2b shows that the rotational frequency of a sandwich complex does increase with the frequency of the driving field, but it does not exactly demonstrate the linear relationship that equation (3) suggests.

We examined the stability of the rotation of sandwich complexes over 60 minutes of observation. The rotational frequency of four sandwich complexes was measured every 5

minutes for 60 minutes, as shown in Figure 3a. The coefficient of variation (standard deviation divided by the mean, times 100%) of the complexes (A–D) was 3.3%, 2.5%, 1.5% and 1.6%, respectively, demonstrating that the rotation of a sandwich complex is fairly stable over a 60 minute observation period. All other measurements reported here were made within an hour of the sandwich complexes being injected into the coverslip fluidic cell.

A dose-response curve of LAM used for measuring the concentration of thrombin in solution is shown in Figure 3b. At each thrombin concentration, the rotation of 15 sandwich complexes was measured, and each point in the figure represents the average of those 15 measurements (\pm standard deviation). The data was fit using the four-parameter logistic Hill equation.^{52–53} The dynamic range of the curve extends from about 1 nM to about 20 nM. Above 20 nM, the curve plateaus. Below 1 nM, there is still a detectable signal down to 300 pM. In the 300 pM to 1 nM range, there was still binding of beads to the mother sphere, but there was no significant difference between the different concentrations. Below 300 pM, no binding of beads to the mother sphere was observed. Similarly, in a control sample (no thrombin), there was also no binding detected. In the absence of the aptamers thrombin does not bind to the spheres and beads. Figure 3b demonstrates the viability of LAM as a tool for measuring the concentration of a protein in solution, with an LOD (limit of detection) of 300 pM.

Screenshots of the rotation of five of the sandwich complexes from Figure 3b are shown in Figure 4. These images show that the number of beads attached to each complex increases with the concentration of thrombin, and that the rotational frequency of the complexes increases with the number of attached beads. These images also show that a qualitative estimate of the protein concentration can be made merely by looking at the complexes under a microscope, without using rotation.

One of the advantages of using the thrombin aptamers are their popularity; many groups have used these aptamers for demonstration of signal transduction techniques. When examining other methods that are sandwich-based and use single-step (non-amplified) methods, reported LODs typically are in the 0.1–1 nM range, including electrochemical detection,^{18, 47} quantum dots,¹¹ Si-nanowire FETs,¹⁹ and fluorescent molecular beacons.⁵⁴ There are many clinically relevant biomarkers found in plasma at concentrations around 1 nM.^{55–56} Within this context, we believe that LAM is certainly competitive with other detection technologies. Moreover, LAM has the advantage of simplicity, robustness and low cost, without requiring sensitive optical readers or other expensive and stationary sensing equipment.

We generated a model in MATLAB to simulate the optimal performance of LAM, assuming perfect mixing and no nonspecific interactions, based on a previously reported two-site immunoassay model.⁵⁷ Considering only specific interactions, there are two primary reactions that take place in our system:



Where P is the protein of interest, Q_1 is the capture aptamer, and Q_2 is the detection aptamer. Also, there are two possible side reactions:



The model is carried out in two parts, capture and detection. In the capture phase, only equation (5) is considered. After the capture reaction has reached equilibrium, the detection phase commences, in which equations (5)–(8) are all considered. The rate constants for the thrombin aptamers were obtained from previously published work.⁵⁸ The model is generated by simultaneously solving the six differential equations below:

$$\frac{d[Q_1]}{dt} = -k_1[Q_1][P] + k_{-1}[Q_1P] - k_4[Q_1][Q_2P] + k_{-4}[Q_1PQ_2] \quad (9)$$

$$\frac{d[Q_2]}{dt} = -k_3[Q_2][P] + k_{-3}[Q_2P] - k_2[Q_1P][Q_2] + k_{-2}[Q_1PQ_2] \quad (10)$$

$$\frac{d[P]}{dt} = -k_1[Q_1][P] + k_{-1}[Q_1P] - k_3[Q_2][P] + k_{-3}[Q_2P] \quad (11)$$

$$\frac{d[Q_1P]}{dt} = k_1[Q_1][P] - k_{-1}[Q_1P] - k_2[Q_1P][Q_2] + k_{-2}[Q_1PQ_2] \quad (12)$$

$$\frac{d[Q_2P]}{dt} = k_3[Q_2][P] - k_{-3}[Q_2P] - k_4[Q_1][Q_2P] + k_{-4}[Q_1PQ_2] \quad (13)$$

$$\frac{d[Q_1PQ_2]}{dt} = k_2[Q_1P][Q_2] + k_4[Q_1][Q_2P] - (k_{-2} + k_{-4})[Q_1PQ_2] \quad (14)$$

The simulated dose-response curve based on this model is shown in Figure 5. Deviations of the experimental data from this simulated dose-response curve could be due to nonspecific interactions between the aptamers and other proteins in solution, imperfect mixing, suboptimal aptamer-bead attachment, or experimental error. The rather abrupt plateau at the top of the dose-response curve is due to the saturation of the mother spheres with magnetic beads before saturation with thrombin; only a few hundred beads can bind to the mother sphere, but over a million thrombin molecules could bind to the mother sphere.

It is our long term goal to develop LAM into a signal transduction method that is suitable for use in a point-of-care clinical setting. In order to achieve this goal, several additional steps

must be taken. We plan to translate LAM off the microscope and measure the rotation of the sandwich complex using a simple, compact-disc-like, laser-and-photodiode setup⁵⁹, together with automated and self-contained mixing, in a microfluidic chip. We also plan to reproduce these results in a biological fluid medium, such as serum. We believe that, after additional development, LAM will be an attractive tool for use, because it will not require fluorescence readers or a microscope, and the actual detector (the laser and photodiode) would be low-cost. We recognize that these goals will require additional work. The goal of this paper is to demonstrate the feasibility of LAM as a signal transduction method for measuring the concentration of a protein in solution, for possible future applications as a point-of-care signal transduction method.

Conclusion

In summary, we have demonstrated that label-acquired magnetorotation is a viable signal transduction method for measuring the concentration of a protein in solution, with a limit of detection of 300 pM of thrombin when using the classic thrombin aptamers. We have shown that the amplitude and frequency response of a sandwich complex generally follow the behavior predicted by the equations that describe superparamagnetic bead behavior. It is our hope for the future that, with further work, LAM will be developed into a viable signal transduction method for point-of-care testing.

Acknowledgments


The authors thank Alex Hrin for creating the video capture LabVIEW program, Ron Smith for assistance with microscopy and magnetic field setup. This research was partially supported by the Department of Homeland Security (DHS) Scholarship and Fellowship Program, administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the U.S. Department of Energy (DOE) and DHS. ORISE is managed by Oak Ridge Associated Universities (ORAU) under DOE contract number DEAC05-06OR23100. All opinions expressed in this paper are the author's and do not necessarily reflect the policies and views of DHS, DOE, or ORAU/ORISE. Additional support came from NSF/DMR grant 0455330 (RK) and NIH R21 EB009550 (RK).

References

1. National Cancer Institute. [Date Accessed: 5/31/2011]
<http://www.cancer.gov/newscenter/pressreleases/2011/NLSTFastFacts>
2. NLSTRT. *Radiology*. 2011; 258:243–253. [PubMed: 21045183]
3. Hecht A, Kinnunen P, McNaughton B, Kopelman R. *J Magn Magn Mater*. 2011; 323:272–278.
4. Ekins RP. *Journal of Pharmaceutical and Biomedical Analysis*. 1989; 7:155–168. [PubMed: 2488616]
5. Engvall E, Perlmann P. *The Journal of Immunology*. 1972; 109:129–135. [PubMed: 4113792]
6. Cho I-H, Paek E-H, Kim Y-K, Kim J-H, Paek S-H. *Anal Chim Acta*. 2009; 632:247–255. [PubMed: 19110101]
7. Guillet C, Fourcin M, Chevalier S, Pouplard A, Gascan H. *Annals of the New York Academy of Sciences*. 1995; 762:407–409. [PubMed: 7668543]
8. Hayes MA, Petkus MM, Garcia AA, Taylor T, Mahanti P. *Analyst*. 2009; 134:533–541. [PubMed: 19238291]
9. Yang X, Li X, Prow TW, Reece LM, Bassett SE, Luxon BA, Herzog NK, Aronson J, Shope RE, Leary JF, Gorenstein DG. *Nucleic Acids Res*. 2003; 31:e54. [PubMed: 12736320]
10. Urdea MS, Warner BD, Running JA, Stempien M, Clyne J, Horn T. *Nucleic Acids Research*. 1988; 16:4937–4956. [PubMed: 3387214]
11. Tennico YH, Hutanu D, Koesdjojo MT, Bartel CM, Remcho VT. *Anal Chem*. 2010; 82:5591–5597. [PubMed: 20545301]
12. Su X-L, Li Y. *Anal Chem*. 2004; 76:4806–4810. [PubMed: 15307792]

13. Soelberg SD, Stevens RC, Limaye AP, Furlong CE. *Anal Chem.* 2009; 81:2357–2363. [PubMed: 19215065]
14. Huang J-G, Lee C-L, Lin H-M, Chuang T-L, Wang W-S, Juang R-H, Wang C-H, Lee CK, Lin S-M, Lin C-W. *Biosensors and Bioelectronics.* 2006; 22:519–525. [PubMed: 16962763]
15. Chinowsky TM, Quinn JG, Bartholomew DU, Kaiser R, Elkind JL. *Sensors and Actuators B: Chemical.* 2003; 91:266–274.
16. Meyerhoff M, Duan C, Meusel M. *Clin Chem.* 1995; 41:1378–1384. [PubMed: 7544708]
17. Dai Z, Yan F, Chen J, Ju H. *Anal Chem.* 2003; 75:5429–5434. [PubMed: 14710822]
18. Cai H, Lee TM-H, Hsing IM. *Sensors and Actuators B: Chemical.* 2006; 114:433–437.
19. Kim KS, Lee H-S, Yang J-A, Jo M-H, Hahn SK. *Nanotechnology.* 2009; 20:235501. [PubMed: 19448297]
20. Pamme N. *Lab Chip.* 2006; 6:24–38. [PubMed: 16372066]
21. Gijjs MAM, Lacharme F, Lehmann U. *Chem Rev.* 2010; 110:1518–1563. [PubMed: 19961177]
22. Osterfeld SJ, Yu H, Gaster RS, Caramuta S, Xu L, Han SJ, Hall DA, Wilson RJ, Sun SH, White RL, Davis RW, Pourmand N, Wang SX. *P Natl Acad Sci USA.* 2008; 105:20637–20640.
23. Edelstein RL, Tamanaha CR, Sheehan PE, Miller MM, Baselt DR, Whitman LJ, Colton RJ. *Biosens Bioelectron.* 2000; 14:805–813. [PubMed: 10945455]
24. Schotter J, Kamp PB, Becker A, Pühler A, Reiss G, Brückl H. *Biosensors and Bioelectronics.* 2004; 19:1149–1156. [PubMed: 15046745]
25. Besse P-A, Boero G, Demierre M, Pott V, Popovic R. *Appl Phys Lett.* 2002; 80:4199–4201.
26. Sandhu A, Handa H, Abe M. *Nanotechnology.* 2010; 21:442001. [PubMed: 20935358]
27. Lee H, Sun E, Ham D, Weissleder R. *Nat Med.* 2008; 14:869–874. [PubMed: 18607350]
28. Chung SH, Hoffmann A, Bader SD, Liu C, Kay B, Makowski L, Chen L. *Appl Phys Lett.* 2004; 85:2971–2973.
29. Choi J-W, Liakopoulos TM, Ahn CH. *Biosensors and Bioelectronics.* 2001; 16:409–416. [PubMed: 11672655]
30. Hayes MA, Polson NA, Phayre AN, Garcia AA. *Analytical Chemistry.* 2001; 73:5896–5902. [PubMed: 11791558]
31. Pamme N, Manz A. *Anal Chem.* 2004; 76:7250–7256. [PubMed: 15595866]
32. Fonnum G, Johansson C, Molteberg A, Morup S, Aksnes E. *J Magn Magn Mater.* 2005; 293:41–47.
33. Fannin PC, Cohen-Tannoudji L, Bertrand E, Giannitsis AT, Mac Oireachtaigh C, Bibette J. *J Magn Magn Mater.* 2006; 303:147–152.
34. Janssen XJA, Schellekens AJ, van Ommerring K, van Ijzendoorn LJ, Prins MWJ. *Biosens Bioelectron.* 2009; 24:1937–1941. [PubMed: 19022651]
35. McNaughton BH, Kehbein KA, Anker JN, Kopelman R. *J Phys Chem B.* 2006; 110:18958–18964. [PubMed: 16986890]
36. Kinnunen P, Sinn I, McNaughton BH, Newton DW, Burns MA, Kopelman R. *Biosensors and Bioelectronics.* 2011; 26:2751–2755. [PubMed: 21095112]
37. Kinnunen P, Sinn I, McNaughton BH, Kopelman R. *Appl Phys Lett.* 2010; 97:223701–223701-3. [PubMed: 21200442]
38. McNaughton BH, Agayan RR, Clarke R, Smith RG, Kopelman R. *Appl Phys Lett.* 2007; 91 -
39. McNaughton BH, Agayan RR, Wang JX, Kopelman R. *Sensor Actuat B-Chem.* 2007; 121:330–340.
40. Turek C, Gold L. *Science.* 1990; 249:505–510. [PubMed: 2200121]
41. Ellington AD, Szostak JW. *Nature.* 1990; 346:818–822. [PubMed: 1697402]
42. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ. *Nature.* 1992; 355:564–566. [PubMed: 1741036]
43. Tasset DM, Kubik MF, Steiner W. *J Mol Biol.* 1997; 272:688–698. [PubMed: 9368651]
44. Cho H, Baker BR, Wachsmann-Hogiu S, Pagba CV, Laurence TA, Lane SM, Lee LP, Tok JBH. *Nano Letters.* 2008; 8:4386–4390. [PubMed: 19367849]
45. Xiao Y, Lubin AA, Heeger AJ, Plaxco KW. *Angewandte Chemie.* 2005; 117:5592–5595.

46. Strehlitz B, Nikolaus N, Stoltenburg R. *Sensors*. 2008; 8:4296–4307.
47. Centi S, Tombelli S, Minunni M, Mascini M. *Anal Chem*. 2007; 79:1466–1473. [PubMed: 17297945]
48. Huang C-C, Cao Z, Chang H-T, Tan W. *Anal Chem*. 2004; 76:6973–6981. [PubMed: 15571349]
49. Milne, G. *Optical Sorting and Manipulation of Microscopic Particles*. University of St. Andrews; 2007.
50. Connolly J, St Pierre TG. *J Magn Magn Mater*. 2001; 225:156–160.
51. Bodker F, Morup S, Linderoth S. *Phys Rev Lett*. 1994; 72:282. [PubMed: 10056105]
52. Baud, M. *Methods of Immunological Analysis*. Masseyeff, R., editor. Vol. vol. 1. New York, NY: VCH Publishers, Inc.; 1993. p. 656-671.
53. Hecht AH, Sommer GJ, Durland RH, Yang X, Singh AK, Hatch AV. *Analytical Chemistry*. 2010; 82:8813–8820.
54. Radi A-E, Acero Sánchez JL, Baldrich E, O'Sullivan CK. *Journal of the American Chemical Society*. 2005; 128:117–124. [PubMed: 16390138]
55. Polanski M, Anderson NL. *Biomarker Insights*. 2006; 2:1–48.
56. Jacobs JM, Adkins JN, Qian W-J, Liu T, Shen Y, Camp DG, Smith RD. *Journal of Proteome Research*. 2005; 4:1073–1085. [PubMed: 16083256]
57. Rodbard D, Feldman Y. *Immunochemistry*. 1978; 15:71–76. [PubMed: 631867]
58. Muller J, Freitag D, Mayer G, Potzsch B. *Journal of Thrombosis and Haemostasis*. 2008; 6:2105–2112. [PubMed: 18826387]
59. McNaughton BH, Kinnunen P, Smith RG, Pei SN, Torres-Isea R, Kopelman R, Clarke R. *J Magn Magn Mater*. 2009; 321:1648–1652.

**Figure 1.**

Schematic of LAM with thrombin as the analyte. (1) 10 μm nonmagnetic mother spheres coated with the 29-mer anti-thrombin aptamer are mixed with thrombin, which binds to the mother spheres. (2) 1 μm magnetic beads coated with the 15-mer anti-thrombin aptamer are mixed with the thrombin-coated mother spheres. The magnetic beads bind to the thrombin attached to the mother sphere, forming a sandwich complex. (3) The sandwich complex is transferred to a rotating magnetic field, where the rotational frequency of the sandwich complex depends on the number of attached magnetic beads.




Figure 2.

(a) Amplitude response curves showing that the rotational frequency of a sandwich complex is proportional to the square of the amplitude of the driving field (with $B = \mu_0 H$). The data are fit with a linear trendline with r^2 values of (A) 0.968, (B) 0.995, and (C) 0.994. (b)

Frequency response curves showing that the rotational frequency of a sandwich complex increases with an increase in the frequency of the driving field.




Figure 3.

(a) The rotational frequency of four sandwich complexes measured every five minutes over the course of an hour. The rotational frequency means, \pm SD (CV%) of the four sandwich complexes (A–D) are 0.0856 ± 0.0028 Hz (3.3%), 0.1523 ± 0.0038 Hz (2.5%), 0.263 ± 0.0040 Hz (1.5%) and 0.448 ± 0.0073 Hz (1.6%), respectively. This demonstrates that the rotation of the sandwich complexes is stable over time. (b) Dose-response curve for the detection of thrombin by LAM. The data are fit by a four-parameter logistic equation ($r^2 = 0.971$). Each data point represents the average \pm SD of 15 sandwich complexes.




Figure 4. Screenshots of five sandwich complexes taken through a 100 \times oil-immersion objective. The thrombin concentration and the rotational frequency of each complex is shown below the picture. The number of magnetic beads on and the rotational frequency of each sandwich complex appears to increase with concentration of thrombin.




Figure 5. Simulated dose-response curve (dotted line) for LAM from a model based on the binding kinetics of the aptamers with thrombin. Also included in the plot are experimental data (dots), from Figure 3b, and a logistic curve fit (dashed line). The abrupt plateau at the top of the predicted dose-response curve represents the saturation of the sensor.